NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Hims & Hers Health Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Hims & Hers Health operates a digital platform delivering telehealth consultations and treatments for various medical conditions through licensed providers. The company provides prescription medications via its own pharmacies, over-the-counter products, and laboratory testing services, primarily through subscription models. It serves customers across the United States, Canada, the United Kingdom, and select European countries.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Hims & Hers Health Inc stock.
Overvalued: intrinsic value $8.63 per share, market price $29.21, margin of safety -238.6% (as of 2026-10-20).
Discounting its cash flows at 14.2% (average of 2 methods) values the shares at $8.63; the price of $29.21 is 239% above that value, and 63% of that value comes from beyond year five.
Leak Score: 43/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
28 more in this industry show a wider margin of safety.
HIMS is overvalued (as of the 2026-10-20 close). Discounting its cash flows at 14.2% (average of 2 methods) values the shares at $8.63; the price of $29.21 is 239% above that value, and 63% of that value comes from beyond year five.
$8.63 per share (as of the 2026-10-20 close), against a market price of $29.21. That is a margin of safety of -238.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
43 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.